860312-72-7

Upstream product

• 75-16-1 methylmagnesium bromide 
• 860312-99-8 1-(N-tert.-butyloxycarbonyl-amino)-2-(S)-phenylethyl methyl ketone 
• 150-30-1 Phenylalanine 
• 5619-07-8 methyl 2-amino-3-phenylpropanoate hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 144899-38-7 DL-3-Amino-2-methyl-4-phenyl-2-butanol 

Downstream Products

• 352438-06-3 4-benzyl-5,5-dimethyloxazolidin-2-one 
• 860312-71-6 3-amino-2-methyl-4-phenylbutan-2-ol hydrochloride 

Relevant academic research and scientific papers

Controllable Intramolecular Unactivated C(sp3)-H Amination and Oxygenation of Carbamates

Dual catalyst-controlled intramolecular unactivated C(sp3)-H amination and oxygenation of carbamates merging visible-light photocatalysis and earth-abundant transition metal catalysis have been reported. Useful amino alcohol and diol derivatives could be selectively obtained from readily available tertiary alcohol derivatives. The possible mechanisms have been proposed via a 1,5-HAT process followed by Lewis acid-controlled cyclization. The nickel and zinc catalysts inhibit the formation of oxygenation and amination products, respectively. An interesting phenomenon of chirality transfer is also observed.

Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease

The present invention is directed to phenylamide and pyridylamide derivative compounds of which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.